New developments in antifungal strategy

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 2, 2004, Pages 269-277

  Shetty, Anjali ^a   Barnes, Rosemary A ^b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Amphotericin B; Combination therapy; Echinocandins; Immunomodulation; Sordarins; Trial design; Triazoles

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ASTEMIZOLE; BARBITURIC ACID DERIVATIVE; BETA CYCLODEXTRIN; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; CYCLOSPORIN; ECHINOCANDIN B DERIVATIVE; ERGOT ALKALOID; FLUCONAZOLE; ITRACONAZOLE; NYSTATIN; OMEPRAZOLE; PHENYTOIN; PIMOZIDE; POSACONAZOLE; QUINIDINE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; TACROLIMUS; TERFENADINE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; CONTINUOUS INFUSION; CRYPTOCOCCOSIS; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SALIVA LEVEL; DRUG TOLERABILITY; ESOPHAGITIS; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; HYPOKALEMIA; INFUSION REACTION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MYCOSIS; NEPHROTOXICITY; PHOTOSENSITIVITY DISORDER; REVIEW; SIDE EFFECT; VISUAL IMPAIRMENT;

EID: 2942560795     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.2.269     Document Type: Review

References (55)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554 (2003).
2. BSMM Mycology Training Working Party Medical Mycology in the UK Manpower crisis threatens the future of UK medical mycology Commun. Dis. Public Health 3, 80-81 (2000).
3. Ascioglu S, Rex JH, Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an internation consensus. Clin. Infect. Dis. 34, 7-14 (2002).
4. Kami M, Kishi Y, Hamaki T et al. The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. An autopsy-based retrospective study of 48 patients. Mycoses 45, 287-294 (2002).
5. Muller FM, Trusen A, Weig M. Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur. J. Paed. 161, 563-574 (2002).
6. Subira M, Martino R, Rovira. M et al. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy confirmed invasive aspergillosis. Ann. Hematol. 82, 80-82 (2003).
7. Hebart H, Loffler J, Meisner C et al. Early detection of Aspergillus infection after allogenic stem cell transplantation by polymerase chain reaction screening. J. Infect. Dis. 181, 1713-1719 (2000).
8. Kawamura S, Maesaki S, Noda T et al. Comparison between PCR and detection of antigen in sera for diagnosis of pulmonary aspergillosis. J. Clin. Microbiol. 37, 218-220 (1999).
9. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35, 359-366 (2002).
10. Rogers PD, Barker KS, Herring V et al. Heat-induced superaggregation of amphotericin B attenuates its ability to induce cytokine and chemokine production in the human monocytic cell line THP-1. Antimicrob. Chemother. 51, 405-408 (2003).
11. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomized controlled trial. Brit. Med. J. 322, 579-582 (2001).
12. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open label observational study. Clin. Infect. Dis. 36, 943-951 (2003).
13. DeBeule K, Van Gestel J. Pharmacology of itraconazole. Drugs 61 (Suppl. 1), 27-37 (2001).
14. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with hematological malignancies. Brit. J. Haematol. 105, 901-911 (1999).
15. Boogaerts M, Winston DJ, Bow EJ et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann. Intern. Med. 135, 412-422 (2001).
16. Chandrasekar PH, Manavathu E. Voriconzole: a second generation triazole. Drugs Today 37, 135-148 (2001).
17. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36, 630-637 (2003).
18. Romero AJ, Le Pogamp P, Nillison L-G, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin. Pharmac. Ther. 71, 226-234 (2002).
19. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver niicrosomes. Antimicrob. Agents Chemother. 46, 3091-3093 (2002).
20. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346, 225-234 (2002).
21. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347, 408-415 (2002).
22. Troke PF, Schwartz S, Ruhnke M et al. Voriconazole therapy in 86 patients with CNS aspergillosis: a retrospective analysis. 43rd ICAAC abstracts. Am. Soc. Microbiol. M-1755, 476 (2003) (Abstract).
23. Lortholary O, Mouas-Dupuy H, Dupont B, Lutsar I, Fain O. Voriconazole for bone aspergillosis: a worldwide experience of 19 cases. 43rd ICAAC abstracts. Am. Soc. Microbiol. M-979, 450 (2003) (Abstract).
24. Ally R, Schurmann D, Kreisel W et al. A randomized, double-blind, double-dummy, multi-center trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33, 1447-1454 (2001).
25. Neely MN, Ghannoum MA. The exciting future of antifungal therapy. Eur J. Clin. Microbiol. Infect Dis. 19, 897-914 (2000).
26. Greenberg RN, Anstead G, Herbrecht R et al. Posaconazole experience in the treatment of zygomycosis. 43rd ICAAC abstracts. Am. Soc. Microbiol. M-1757, 476 (2003) (Abstract).
27. Ullmann AJ, Cornely O A, Burchardt A et al. Safety and efficacy of posaconazole (pos) in a pharmacokinetic study in patients with febrile neutropenia (FN) or refractory invasive fungal infections (RIFI). 43rd ICAAC abstracts. Am. Soc. Microbiol. M-1257, 474 (2003) (Abstract).
28. Kartsonis N, Dinubile MJ, Bartizal K et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J. Acquir. Immun. Defic. Syndr. 31, 183-187 (2002).
29. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347, 2020-2029 (2002).
30. Kartsonis N, Saah A, Lipka J, Taylor A, Sable C. Salvage therapy with caspofungin for invasive aspergillosis (IA): results from the CAS compassionate use study. 43rd ICAAC abstracts. Am. Soc. Microbiol. M-981, 451 (2003) (Abstract).
31. Maertens J, Raad I, Petrikkos G et al. Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungal agents: analysis of 90 patients. 42nd ICAAC abstracts. Am. Soc. Microbiol. (2002) (Abstract M-868).
32. Walsh T, Sable C, De Pauw B et al. A randomized, double-blind, multicenter trial of caspofungin vs. liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients. 43rd ICAAC abstracts. Am. Soc. Microbiol. M-1761, 477 (2003) (Abstract).
33. Van Burik J, Ratanatharathorn V, Lipton J et al. Randomized double blind trial of micafunginversus fluconazole for prophylaxis of invasive fubgal infection in patients undergoing hematopoietic stem cell transplant. 42nd ICAAC abstracts. Am. Soc. Microbiol. (2002) (Abstract 1238).
34. Ullmann AJ, Van Burik JA, McSweeney P et al. An open Phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children. 13th Eur. Congress Clin. Microbiol. Infec. Dis. Abstracts (2003) (Abstract 0400).
35. Krause D, Goldstein B, Wible M, Kilfoil G, Henkel T. A Phase II-dose ranging study of the safety and efficacy of anidulafungin in invasive candidiasis. 13th Eur. Congress Clin. Microbiol. Infec. Dis. Abstracts (2003) (Abstract 403).
36. Martinez A, Aviles P, Jimenez E, Caballero J, Gargallo-Viola D. Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis. Antimicrob. Agents Chemother. 44, 3389-3394 (2000).
37. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Clin. Infect. Dis. 30, 662-678 (2000).
38. Mayanja-Kizza H, Oishi K, Mitarai S et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin. Infect. Dis. 26, 1362-1366 (1998).
39. Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy 21, S149-S164 (2001).
40. Lewis RE, Lund BC, Klepser ME, Ernst EJ, Pfaller MA. Assessment of antifungal activites of fluconazole and amphotericin administered alone and in combination against a C. albicans using a dynamic in vitro mycotic infection model. Antimicrob. Agents Chemother. 42, 1382-1386 (1998).
41. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36, 1221-1228 (2003).
42. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98, 292-299 (2003).
43. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46, 245-247 (2002).
44. Romani L. Host immune reactivity and antifungal chemotherapy: the power of being together. J. Chemother. 13, 347-353 (2001).
45. Mencaci A, Cenci E, Bacci A, Bistoni F, L Romani. Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis. J. Infect. Dis. 181, 686-694 (2000).
46. Oncology Association. Update of recommendations for the use of hematopoietic colony stimulating factors: evidence-based clinical practice guidelines. J. Clin. Oncol. 14, 1957-1960 (1996).
47. Volpi I, Perruccio K, Tosti A et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 97, 2514-2521 (2001).
48. Poynton CH, Barnes RA, Rees J. Interferon-γ in the treatment of deep-seated fungal infection in acute leukemia. Clin. Infect. Dis. 26, 239-240 (1998).
49. Cenci E, Mencacci A, Del Sero G, Bistoni F, Romani L. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an Interleukin-4 antagonist. J. Infect. Dis. 176, 217-226 (1997)
50. Kibbler CC, Seaton S, Barnes RA et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J. Hosp. Infect. 54, 18-24 (2003).
51. Hegener P, Troke P, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 12, 2227-2228 (1998).
52. Villaneuva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33, 1529-1535 (2001).
53. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. 46, 451-457 (2002).
54. Mattiuzzi GN, Kantarjian H, Alvarado G. Intravenous itraconazole (ITRA) versus caspofungin (CASPO) prophylaxis in patients (PTS) with acute myelogenous leukaemia (AML) and myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC). 43rd ICAAC Abstracts. Am. Soc. Microb. M-984, 451 (2003) (Abstract).
55. Krause DS, Henkel T. Goldstein BP, Walsh TJ. Anidulafungin vs. fluconazole in esophageal candidiasis: a Phase III, randomized, double-blind, multicenter trial. 43rd ICAAC Abstracts. Am. Soc. Microb. (2003) (Abstract M-1760).